Introduction
============

The recent sequencing technologies and genome-wide analysis have indicated that only 2% of the genome is in protein-encoded regions and that the majority of the genome is the so-called dark matter that is transcribed into noncoding RNAs (ncRNAs).[@b1-ott-11-791]--[@b3-ott-11-791] These ncRNAs are classified as short and long ncRNAs depending on the nucleotide size. Long ncRNAs (lncRNAs) are commonly defined as non-protein-coding transcripts longer than 200 nucleotides.[@b4-ott-11-791],[@b5-ott-11-791] They are crucial players in a wide range of biologic processes on the epigenetic, transcriptional, or posttranscriptional level, and are the important regulators of pathophysiological activities such as cell growth, invasion, apoptosis, and metastasis.[@b6-ott-11-791]--[@b8-ott-11-791] So far, more than 3000 lncRNAs have been found, among which the HOX transcript antisense intergenic RNA (HOTAIR) is the mostly widely studied. HOTAIR is a 2.2 kb lncRNA that is transcribed in antisense orientation from the homebox C (HOXC) gene on chromosome 12q13.13. HOTAIR 5′-domain recruits the Polycomb Repressive Complex 2, leading to histone H3 lysine 27 trimethylation (H3K27me3) in the HOXD locus, and HOTAIR 3′-domain interacts with LSD1/REST/CoREST complex, to regulate the metastasis suppressor genes silence.[@b9-ott-11-791],[@b10-ott-11-791] Clinical and biochemical studies have indicated that deregulation of HOTAIR is a powerful indicator of poor prognosis and malignant progression for several cancers such as ovarian cancer, gastric cancer, and lung cancer.[@b11-ott-11-791]--[@b13-ott-11-791]

Genetic variants, mainly composed of single-nucleotide polymorphisms (SNPs), have long been confirmed in various loci of the genome. These variants may exert various influences on the expression or function of a particular gene.[@b14-ott-11-791],[@b15-ott-11-791] Even with the potential importance of HOTAIR in carcinogenesis, only a few studies have investigated the effects of HOTAIR SNPs on cancer susceptibility. For example, Guo et al reported that the mutated T allele of rs12826786 in HOTAIR could increase the risk of developing gastric cancer and was associated with TNM stage. In addition, higher expression levels of HOTAIR were found in tumor tissues, and rs12826786 SNP had a genotype-specific effect on HOTAIR expression.[@b16-ott-11-791] However, in another case--control study conducted by Ulger et al, HOTAIR rs12826786 (C/T) polymorphism was not playing any major role in genetic susceptibility to gastric carcinogenesis in Turkish population.[@b17-ott-11-791] As for HOTAIR rs7958904 (G/C), Jin et al found that the rs7958904 CC genotype was related to an increased risk of cervical cancer compared with the GG/GC genotypes. Their MTT assay demonstrated a growth-promoting role of rs7958904 C allele on cervical cancer cells.[@b18-ott-11-791] On the contrary, Xue et al revealed that individuals with rs7958904 CC genotype had a significantly decreased risk of colorectal cancer in both stages 1 and 2, compared with those carrying GG genotype.[@b19-ott-11-791]

To address the inconsistency among different case--control studies, some meta-analyses have been performed to draw a conclusion between HOTAIR polymorphisms and cancer susceptibility. Chu et al pooled eight articles on three HOTAIR polymorphisms and concluded that HOTAIR rs920778 increased the cancer risk in the recessive model.[@b20-ott-11-791] Meanwhile, Lv et al summarized five HOTAIR polymorphisms from 16 studies, showing that the rs920778 (C/T) polymorphism was associated with increased risk of overall cancer in the recessive model, while the rs7958904 (G/C) polymorphism was associated with decreased overall risk of cancer in all genetic models.[@b21-ott-11-791] Since then, several new case--control studies have been published, some of which reported controversial results compared with previous publications. Moreover, more types of polymorphisms have been explored, providing a perspective to a further systemic review. In this study, we comprehensively collected and assessed all the available articles using meta-analysis with the aim to better clarify the association between currently reported HOTAIR polymorphisms and cancer susceptibility.

Materials and methods
=====================

Search for eligible literature
------------------------------

A comprehensive electronic search was performed using PubMed, Embase, Medline (Ovid), Weipu, Wanfang, and CNKI for studies published from January 2007 to July 2017. The following keywords were variably combined: "cancer", "malignancy", "HOTAIR", "lncRNA", "polymorphism", "variant", and "mutation". The search was updated every week until July 15, 2017.

Inclusion and exclusion criteria
--------------------------------

Articles fulfilling the following criteria were included: 1) analyzed HOTAIR polymorphisms in cancer; 2) provided sufficient data in both case and control groups to calculate the odds ratios (ORs) and the corresponding 95% CIs; 3) studied the polymorphisms that appeared in at least two publications; and 4) case--control studies. When duplicate data were present in different articles, only the latest one would be included. Meanwhile, articles that did not fulfill the criteria mentioned above were excluded.

Data extraction
---------------

Two investigators independently reviewed all potential studies. The following items were extracted: first author, year of publication, ethnicity, SNPs, cancer type, source of control, genotyping method, adjusted risk factors, and genotype distributions in cases and controls. Any discrepancies were resolved by discussion with a third investigator until a consensus was reached.

The Newcastle--Ottawa Scale (NOS) was used to investigate the quality of included studies. Three aspects of selection, comparability, and exposure (nine scores in total) were carefully evaluated. Studies with scores higher than 5 were included (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>).[@b49-ott-11-791]

Statistical analysis
--------------------

Pooled ORs and corresponding 95% CIs were calculated to estimate the strength of the association between different HOTAIR SNPs and cancer risk. All SNPs were considered as binary variables, and five comparative models were used as follows: recessive genotype vs heterozygous genotype + dominant wild type, recessive genotype + heterozygous genotype vs dominant wild type, heterozygous genotype vs dominant wild type + recessive genotype, recessive genotype vs dominant wild type, and mutant allele vs wild-type allele. The *Z*-test was conducted to determine the significance of the pooled ORs where *P*\<0.05 was interpreted as statistically significant. Higgins *I*^2^ test was used to assess heterogeneity among studies. When *I*^2^ was \<50%, a fixed-effects model was used, indicating the lack of heterogeneity; otherwise, a random-effects model was applied. The presence of publication bias was evaluated by the inspection of funnel plots. When the funnel plots showed visible asymmetry, Egger's test was performed to further measure the bias, which was considered as existing when *P*\<0.05. All analyses were undertaken using Revman 5.2 software (Cochrane Collaboration, Copenhagen, Denmark) with the exception of the Egger's test, which was performed using STATA 14.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Search results
--------------

The initial search yielded 337 publications, 262 of which were excluded for being irrelevant to HOTAIR polymorphisms, by reading titles and abstracts. On further evaluation, 37 articles were either biochemical studies or reviews and were therefore ruled out; 18 articles focused on non-cancer diseases such as rheumatoid arthritis and hearing loss; 1 article explored the relationship between cervical cancer risk and HOTAIR rs2366152 polymorphisms, which were not repeated in other published studies, resulting in the impossibility of data pooling;[@b22-ott-11-791] and 1 article focused on the HOTAIR rs7958904 polymorphisms in lung cancer, but failed to offer detailed genotype information data.[@b23-ott-11-791] Therefore, we enrolled 18 articles of 36 studies in this meta-analysis ([Figure 1](#f1-ott-11-791){ref-type="fig"}).[@b16-ott-11-791]--[@b19-ott-11-791],[@b24-ott-11-791]--[@b37-ott-11-791]

Study characteristics
---------------------

Among the 36 enrolled case--control studies, six HOTAIR polymorphisms were analyzed (rs7958904, rs4759314, rs874945, rs12826786, rs1899663, and rs920778), while 10 cancer types were reported (breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, glioma, lung cancer, ovarian cancer, prostate cancer, and thyroid cancer). Twelve articles were about Chinese population, four were about Turkish, one was about Iranian, and one was about Portuguese. The source of control was also retrieved. Despite the fact that there were 4 articles that failed to mention the detailed control source, 11 articles were hospital based and 3 were population based. The NOS showed that 14 articles were of moderate quality (NOS score of 6 or 7) and 4 were of high quality (NOS score of 8 or 9). All studies reported the numbers of corresponding genotypes as to recessive mutants, heterogeneous mutants, and dominant wild types for both case and control groups. Adjusted variables that might affect the ORs were also summarized for each publication ([Table 1](#t1-ott-11-791){ref-type="table"}).

Quantitative data analysis
--------------------------

As shown in [Tables 2](#t2-ott-11-791){ref-type="table"} and [3](#t3-ott-11-791){ref-type="table"}, six HOTAIR polymorphisms were analyzed in this meta-analysis. For rs12826786 (C/T), five studies including 1,048 cases and 1,432 controls were evaluated. The fixed-effects models proposed a significant association between C-to-T mutation and cancer risk (TT vs CC+CT: OR =1.55, 95% CI =1.19, 2.03; TT+CT vs CC: OR =1.23, 95% CI =1.04, 1.46; TT vs CC: OR =1.67, 95% CI =1.24, 2.24; T vs C: OR =1.24, 95% CI =1.09, 1.40), while heterozygous mutants alone failed to display statistically significant OR ([Figure 2A and B](#f2-ott-11-791){ref-type="fig"}). The results for rs920778 (C/T) were similar. Nine studies with 11,442 participants and seven cancer types were pooled. Recessive mutants presented significantly higher cancer risk when compared with either remaining genotypes or homozygous wild types (TT vs CC+CT: OR =1.73, 95% CI =1.30, 2.30; TT vs CC: OR =1.83, 95% CI =1.25, 2.68). The mutant containing genotypes and mutant allele T also showed statistical significance in elevated cancer risk (TT+CT vs CC: OR =1.40, 95% CI =1.16, 1.70; T vs C: OR =1.37, 95% CI =1.18, 1.59), as shown in [Figure 2C and D](#f2-ott-11-791){ref-type="fig"}. The stratified analysis of 10,508 Chinese was consistent with the overall group results. Thus, it can be concluded that rs12826786 (C/T) and rs920778 (C/T) were correlated with increased cancer risk.

The results for rs7958904 (G/C) polymorphisms were less direct. Four studies including 8,816 Chinese participants were analyzed. The meta-analysis showed that the heterozygous mutants alone and combined with recessive mutants posed lower cancer risks (GC vs GG+CC: OR =0.89, 95% CI =0.82--0.98; CC+GC vs GG: OR =0.84, 95% CI =0.71--0.99). Notably, three out of four studies reported that G-to-C mutation could decrease colorectal and ovarian cancer risks, while one study pointed that CC genotype was related to increased cervical cancer risk. Therefore, it is hard to conclude that rs7958904 (G/C) polymorphisms are related to overall cancer susceptibility. However, this inconsistency indicated that rs7958904 (G/C) polymorphisms might play different roles in different types of cancer.

As to the remaining three types of polymorphisms (rs4759314, rs874945, and rs1899663), no significant association was found between mutant genotypes (or alleles) and cancer susceptibility in the corresponding effect models, either for overall population or for Chinese subgroups. Even though allele A implied a cancer-prone tendency (A vs G: OR =1.09; 95% CI =1.00--1.18) in rs874945 (G/A) polymorphisms, it is impossible to draw any significant conclusion.

Publication bias
----------------

The publication bias was first assessed by visually examining the funnel plots ([Figure 3](#f3-ott-11-791){ref-type="fig"}). Studies on rs4759314, rs874945, rs12826786, and rs1899663 were symmetric, while the existence of bias was indicated in rs7958904 and rs920778. Egger's test was then performed in the two polymorphisms. The results demonstrated no significant bias in the two polymorphisms (*P*\>0.05, data not shown).

Discussion
==========

lncRNAs are a crucial class of RNAs involved in multiple biologic processes such as proliferation and progression of cancer, despite so often being branded as transcriptional noise.[@b38-ott-11-791],[@b39-ott-11-791] Especially, lncRNA HOTAIR, which is coded from the HOXC locus, has been identified to participate in the development and metastasis of malignancies.[@b40-ott-11-791],[@b41-ott-11-791] Several biochemical studies suggested that HOTAIR could not only increase Polycomb Repressive Complex 2 recruitment to the genomic positions of target genes to promote malignant transformation but also sponge miR-331-3p to regulate HER2 expression.[@b42-ott-11-791]--[@b44-ott-11-791] Clinically, unregulated expression of HOTAIR was found to be a powerful indicator of poor prognosis for several cancers.[@b45-ott-11-791],[@b46-ott-11-791] Since the *Homo sapiens* HOTAIR gene contains many SNPs, recent molecular epidemiologic studies have focused on the association between HOTAIR polymorphisms and cancer susceptibility. Although multiple SNPs and cancer types were explored, no consensus was reached, possibly due to limited sample sizes and variant participant characteristics. In order to draw a more concrete conclusion, we comprehensively searched the existing publications and performed a meta-analysis for six HOTAIR polymorphisms and 10 cancer types by enrolling 36 studies from 18 articles.

Our results showed that polymorphisms of rs12826786 (C/T) and rs920778 (C/T) were correlated with increased cancer risk. Both T-containing genotypes and T alleles were correlated with cancer susceptibility, especially in Chinese population. HOTAIR rs12826786 (C/T) and rs920778 polymorphisms are respectively located within an intronic promoter region and enhancer region, where specific mutations may exert a genotype-specific transcriptional effect on HOTAIR expression.[@b33-ott-11-791],[@b35-ott-11-791] Previous luciferase assay showed that the substitution of cytosine (C) by thymine (T) in either of the two loci could result in a higher HOTAIR expression, which was pervasively detected in both primary and metastasized tumors of breast cancer, colorectal cancer, lung cancer, and others.[@b19-ott-11-791],[@b23-ott-11-791],[@b24-ott-11-791] Moreover, recent case--control studies revealed that high expression of HOTAIR was correlated with lower survival rates.[@b29-ott-11-791],[@b33-ott-11-791],[@b37-ott-11-791] All these findings are consistent with the results of this meta-analysis, highlighting the roles of SNPs in cancer risk and prognosis.

Our meta-analysis also indicated that the remaining four polymorphisms (rs7958904, rs4759314, rs874945, and rs1899663) were not associated with cancer risk. We noticed that the results for rs7958904 (G/C) polymorphisms were different from a previous meta-analysis, which indicated a decreased cancer risk for G-to-C mutation. The reason lies in the inclusion of the cervical cancer study.[@b18-ott-11-791] The authors discovered that the rs7958904 (G/C) polymorphisms conferred an increased risk of cervical cancer. By performing functional assay and MTT assay, they found a higher HOTAIR expression in cervical cancer tissues with rs7958904 CC genotype and a growth-promoting role of rs7958904 C allele on cervical cancer cell line. However, the other three studies reported opposite results in both case--control studies and biochemical assays.[@b19-ott-11-791],[@b32-ott-11-791],[@b37-ott-11-791] As a result, our meta-analysis showed an insignificant result. This reflects the complex function of HOTAIR gene and its variants.[@b18-ott-11-791] It also suggests that HOTAIR polymorphisms might play different biologic roles in different types of cancer.

Despite our efforts to include all the eligible publications, several limitations to our meta-analysis should be noticed. First, the populations of included studies were Chinese, Turkish, Iranian, and Portuguese. It is epidemiologically known that other ethnicities such as blacks and Hispanics are also caner susceptible;[@b47-ott-11-791],[@b48-ott-11-791] thus, the lack of data for these populations might affect the overall results. However, it is worth noting that our stratified analysis may draw a more convincing conclusion for Chinese population. Second, our evaluation mainly focused on unadjusted results due to the insufficient data of several risk factors, while the majority of studies only matched age and gender between cases and controls; the possible imbalance among risk factors may cause distorted results. Moreover, although the number of pooled participants was so far the largest, the included cancer types were still limited. Thus, caution must be preserved when explaining the results to other cancers, especially when we noticed that HOTAIR polymorphisms might function differently in different cancers. Therefore, more studies on various cancer types are needed to help reach a consensus.

In conclusion, our meta-analysis showed that HOTAIR polymorphisms of rs12826786 and rs920778 were correlated with increased cancer risk, while rs7958904, rs4759314, rs874945, and rs1899663 were not. Our meta-analysis was the first to explore the relationship between rs12826786 polymorphisms and cancer susceptibility. It also raised the statistic evidence of discrepant HOTAIR behaviors in different cancer types. Clarifying the environmental and lifestyle risk factors and exploring wider types of cancer are required for future studies to help us draw a concrete conclusion.
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![Representative forest plots.\
**Notes:** (**A**) TT vs CC+TT of rs12826786 (C/T) polymorphisms. (**B**) T vs C of rs12826786 (C/T) polymorphisms. (**C**) TT vs CC+TT in overall group analysis of rs920778 (C/T) polymorphisms. (**D**) T vs C in overall group analysis of rs920778 (C/T) polymorphisms. \*Cervical cancer group.\
**Abbreviation:** *df*, degrees of freedom.](ott-11-791Fig2){#f2-ott-11-791}

![Representative funnel plots of publication bias.\
**Notes:** (**A**) TT vs CC+TT of rs12826786 (C/T) polymorphisms. (**B**) T vs C of rs12826786 (C/T) polymorphisms. (**C**) TT vs CC+TT in overall group analysis of rs920778 (C/T) polymorphisms. (**D**) T vs C in overall group analysis of rs920778 (C/T) polymorphisms.\
**Abbreviations:** OR, odds ratio; SE, standard error.](ott-11-791Fig3){#f3-ott-11-791}

###### 

Characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                 Year   Ethnicity    SNPs                Cancer type         Source of control   Genotyping method   Adjusted factors                                                                         Study quality
  ----------------------------------------- ------ ------------ ------------------- ------------------- ------------------- ------------------- ---------------------------------------------------------------------------------------- ---------------
  Bayram et al[@b25-ott-11-791]             2016   Turkish      rs12826786 (C/T)    Breast cancer       Hospital            TaqMan              Age                                                                                      7

  Bayram et al[@b24-ott-11-791]             2015   Turkish      rs920778 (T/C)      Gastric cancer      Hospital            TaqMan              Age, gender, smoking, drinking                                                           7

  Bayram et al[@b25-ott-11-791]             2015   Turkish      rs920778 (T/C)      Breast cancer       Hospital            TaqMan              Age, gender                                                                              7

  Du et al[@b27-ott-11-791]                 2015   Chinese      rs4759314 (A/G)     Gastric cancer      Hospital            TaqMan              Age, gender                                                                              8

  Guo et al[@b16-ott-11-791]                2015   Chinese      rs4759314 (A/G)\    Gastric cancer      Hospital            PCR-RFLP            Age, gender, smoking status                                                              7
                                                                rs12826786 (C/T)                                                                                                                                                         

  Jin et al[@b18-ott-11-791]                2017   Chinese      rs7958904 (G/C)\    Cervical cancer     Hospital            TaqMan              Not known                                                                                7
                                                                rs4759314 (A/G)\                                                                                                                                                         
                                                                rs874945 (G/A)                                                                                                                                                           

  Pan et al[@b28-ott-11-791]                2016   Chinese      rs4759314 (A/G)\    Gastric cancer      Population          PCR-RFLP            Age, gender                                                                              7
                                                                rs1899663 (G/T)\                                                                                                                                                         
                                                                rs920778 (C/T)                                                                                                                                                           

  Qiu et al[@b30-ott-11-791]                2016   Chinese      rs920778 (T/C)      Ovarian cancer      Not known           TaqMan              Age, parity, smoking, menopausal status                                                  6

  Qiu et al[@b30-ott-11-791]                2016   Chinese      rs920778 (C/T)      Cervical cancer     Not known           TaqMan              Age                                                                                      6

  Taheri et al[@b31-ott-11-791]             2017   Iranian      rs4759314 (A/G)\    Prostate cancer     Hospital            ARMS-PCR            Age, BMI, smoking                                                                        7
                                                                rs12826786 (C/T)\                                                                                                                                                        
                                                                rs1899663 (G/T)                                                                                                                                                          

  Ulger et al[@b17-ott-11-791]              2017   Turkish      rs12826786 (C/T)    Gastric cancer      Hospital            TaqMan              Age, gender, smoking, drinking                                                           7

  Wu et al[@b32-ott-11-791]                 2016   Chinese      rs7958904 (G/C)\    Ovarian cancer      Not known           RT-PCR              Age, drinking, BMI                                                                       6
                                                                rs4759314 (A/G)\                                                                                                                                                         
                                                                rs874945 (G/A)                                                                                                                                                           

  Xavier-Magalhães et al[@b33-ott-11-791]   2017   Portuguese   rs12826786 (C/T)\   Glioma              Population          PCR-RFLP            Age, gender                                                                              8
                                                                rs920778 (C/T)                                                                                                                                                           

  Xue et al[@b19-ott-11-791]                2015   Chinese      rs7958904 (G/C)\    Colorectal cancer   Hospital            TaqMan              Age, gender, drinking                                                                    7
                                                                rs4759314 (A/G)\                                                                                                                                                         
                                                                rs874945 (G/A)                                                                                                                                                           

  Yan et al[@b34-ott-11-791]                2015   Chinese      rs4759314 (A/G)\    Breast cancer       Population          PCR-RFLP            Age, menopause age, menstrual history, No of pregnancy, No of abortion, breast feeding   8
                                                                rs1899663 (G/T)\                                                                                                                                                         
                                                                rs920778 (C/T)                                                                                                                                                           

  Zhang et al[@b35-ott-11-791]              2014   Chinese      rs4759314 (A/G)\    Esophageal cancer   Hospital            RT-PCR              Age, gender                                                                              8
                                                                rs1899663 (G/T)\                                                                                                                                                         
                                                                rs920778 (C/T)                                                                                                                                                           

  Zhu et al[@b36-ott-11-791]                2016   Chinese      rs4759314 (A/G)\    Thyroid cancer      Not known           PCR-RFLP            Age, gender                                                                              6
                                                                rs1899663 (G/T)\                                                                                                                                                         
                                                                rs920778 (C/T)                                                                                                                                                           

  Zhu et al[@b37-ott-11-791]                2016   Chinese      rs7958904 (G/C)     Colorectal cancer   Hospital            TaqMan              Age, gender, smoking, drinking, meal regularity, grain intake                            7
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ARMS-PCR, amplification-refractory mutation system-polymerase chain reaction; BMI, body mass index; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; RT-PCR, real-time polymerase chain reaction; SNP, single-nucleotide polymorphism.

###### 

Genotype distributions of included studies

  SNP                                       References                      Year                Cancer type       Case number   Control number   Case   Control                         
  ----------------------------------------- ------------------------------- ------------------- ----------------- ------------- ---------------- ------ --------- ------- ----- ------- -------
  rs7958904 (G/C)                           Jin et al[@b18-ott-11-791]      2017                Cervical caner    1,153         1,292            86     427       640     63    494     735
  Wu et al[@b32-ott-11-791]                 2016                            Ovarian cancer      1,000             1,000         51               355    594       87      380   533     
  Xue et al[@b19-ott-11-791]                2015                            Colorectal cancer   1,145             1,201         74               399    672       99      456   646     
  Zhu et al[@b36-ott-11-791]                2016                            Colorectal cancer   394               394           38               141    215       52      161   181     
  rs4759314 (A/G)                           Du et al[@b27-ott-11-791]       2015                Gastric cancer    1,275         1,644            6      186       1,083   8     172     1,464
  Guo et al[@b16-ott-11-791]                2015                            Gastric cancer      515               654           1                53     461       1       64    589     
  Jin et al[@b18-ott-11-791]                2017                            Cervical cancer     1,174             1,304         4                158    1,012     2       140   1,162   
  Pan et al[@b28-ott-11-791]                2016                            Gastric cancer      500               1,000         1                48     451       3       83    914     
  Taheri et al[@b31-ott-11-791]             2017                            Prostate cancer     125               250           7                32     86        6       81    163     
  Wu et al[@b32-ott-11-791]                 2016                            Ovarian cancer      1,000             1,000         41               140    819       23      125   852     
  Xue et al[@b19-ott-11-791]                2015                            Colorectal cancer   1,147             1,203         1                135    1,011     9       157   1,037   
  Yan et al[@b34-ott-11-791]                2015                            Breast cancer       502               504           1                50     451       2       54    448     
  Zhang et al[@b35-ott-11-791]              2014                            Esophageal cancer   1,000             1,000         2                81     917       1       89    910     
  Zhu et al[@b36-ott-11-791]                2016                            Thyroid cancer      600               600           2                58     540       2       45    553     
  rs874945 (G/A)                            Jin et al[@b18-ott-11-791]      2017                Cervical cancer   1,171         1,289            43     383       745     43    394     852
  Wu et al[@b32-ott-11-791]                 2016                            Ovarian cancer      1,000             1,000         52               283    665       44      279   677     
  Xue et al[@b19-ott-11-791]                2015                            Colorectal cancer   1,147             1,202         40               356    751       39      346   817     
  rs12826786 (C/T)                          Bayram et al[@b25-ott-11-791]   2016                Breast cancer     123           122              30     51        42      14    64      44
  Guo et al[@b16-ott-11-791]                2015                            Gastric cancer      515               654           30               200    285       19      232   403     
  Taheri et al[@b31-ott-11-791]             2017                            Prostate cancer     128               250           32               70     26        42      125   83      
  Ulger et al[@b17-ott-11-791]              2017                            Gastric cancer      105               207           20               47     38        35      99    73      
  Xavier-Magalhães et al[@b33-ott-11-791]   2017                            Glioma              177               199           16               77     84        21      84    94      
  rs1899663 (G/T)                           Pan et al[@b28-ott-11-791]      2016                Gastric cancer    490           1,020            6      118       366     13    255     752
  Taheri et al[@b31-ott-11-791]             2017                            Prostate cancer     127               250           22               70     35        40      133   77      
  Yan et al[@b34-ott-11-791]                2015                            Breast cancer       502               361           14               149    339       20      158   326     
  Zhang et al[@b35-ott-11-791]              2014                            Esophageal cancer   1,000             1,000         19               256    725       26      250   724     
  Zhu et al[@b37-ott-11-791]                2016                            Thyroid cancer      580               600           7                151    422       12      175   413     
  rs920778 (C/T)                            Bayram et al[@b24-ott-11-791]   2015                Gastric cancer    104           209              32     52        20      66    105     38
  Bayram et al[@b25-ott-11-791]             2015                            Breast cancer       123               122           40               52     31        41      66    15      
  Pan et al[@b28-ott-11-791]                2016                            Gastric cancer      800               1,600         59               321    420       45      575   980     
  Qiu et al[@b30-ott-11-791]                2016                            Ovarian cancer      329               680           25               69     235       22      78    580     
  Qiu et al[@b30-ott-11-791]                2016                            Cervical cancer     215               430           47               78     90        54      150   226     
  Xavier-Magalhães et al[@b33-ott-11-791]   2017                            Glioma              177               199           82               71     24        90      84    25      
  Yan et al[@b34-ott-11-791]                2015                            Breast cancer       502               504           339              151    12        296     190   18      
  Zhang et al[@b35-ott-11-791]              2014                            Esophageal cancer   2,098             2,150         181              826    1,091     78      749   1,323   
  Zhu et al[@b37-ott-11-791]                2016                            Thyroid cancer      600               600           53               259    288       19      209   372     

**Abbreviations:** Dom, dominant wild type; Hetero, heterozygous genotype; Rec, recessive genotype; SNP, single-nucleotide polymorphism.

###### 

Summary of different comparative results of HOTAIR polymorphisms on cancer susceptibility

  SNP                Comparative type   Overall and subgroup   Participants        OR (95% CI)         *Z*-value   *P*-value   *I*^2^ (%)   Effect model
  ------------------ ------------------ ---------------------- ------------------- ------------------- ----------- ----------- ------------ --------------
  rs7958904 (G/C)    CC vs GG+GC        Overall                8,816               0.82 (0.53, 1.27)   0.78        0.38        85           R
  CC+GC vs GG        Overall            8,816                  0.84 (0.71, 0.99)   2.06                0.04        71          R            
  GC vs GG+CC        Overall            7,579                  0.89 (0.82, 0.98)   2.52                0.01        0           F            
  CC vs GG           Overall            4,766                  0.77 (0.47, 1.24)   1.08                0.28        87          R            
  C vs G             Overall            15,158                 0.86 (0.72, 1.03)   1.67                0.10        85          R            
  rs4759314 (A/G)    GG vs AA+AG        Overall                18,235              1.37 (0.96, 1.94)   1.74        0.08        0            F
  Chinese            17,860             1.29 (0.89, 1.87)      1.34                0.18                0           F                        
  GG+AG vs AA        Overall            18,235                 1.11 (0.97, 1.27)   1.50                0.13        52          R            
  Chinese            17,860             1.13 (0.98, 1.30)      1.70                0.09                54          R                        
  AG vs AA+GG        Overall            18,235                 1.09 (0.95, 1.25)   1.22                0.22        51          R            
  Chinese            17,860             1.12 (1.02, 1.23)      2.38                0.02                47          F                        
  GG vs AA           Overall            16,140                 1.38 (0.97, 1.96)   1.78                0.08        0           F            
  Chinese            15,878             1.31 (0.90, 1.90)      1.42                0.15                0           F                        
  G vs A             Overall            36,470                 1.12 (0.98, 1.27)   1.64                0.10        54          R            
  Chinese            35,720             1.13 (0.98, 1.30)      1.66                0.10                58          R                        
  rs874945 (G/A)     AA vs GG+GA        Overall                6,809               1.13 (0.88, 1.44)   0.95        0.34        0            F
  AA+GA vs GG        Overall            6,809                  1.10 (0.99, 1.21)   1.84                0.07        0           F            
  GA vs GG+AA        Overall            6,809                  1.08 (0.98, 1.20)   1.50                0.13        0           F            
  AA vs GG           Overall            4,768                  1.16 (0.90, 1.48)   1.14                0.26        0           F            
  A vs G             Overall            13,618                 1.09 (1.00, 1.18)   1.90                0.06        0           F            
  rs12826786 (C/T)   TT vs CC+CT        Overall                2,480               1.55 (1.19, 2.03)   3.21        0.01        40           F
  TT+CT vs CC        Overall            2,480                  1.23 (1.04, 1.46)   2.47                0.01        29          F            
  CT vs CC+TT        Overall            2,480                  1.04 (0.89, 1.23)   0.50                0.62        23          F            
  TT vs CC           Overall            1,431                  1.67 (1.24, 2.24)   3.41                0.01        48          F            
  T vs C             Overall            4,960                  1.24 (1.09, 1.40)   3.35                0.01        35          F            
  rs1899663 (G/T)    TT vs GG+GT        Overall                6,073               0.82 (0.60, 1.12)   1.24        0.22        0            F
  Chinese            5,696              0.72 (0.50, 1.05)      1.68                0.09                0           F                        
  TT+GT vs GG        Overall            6,073                  0.94 (0.84, 1.05)   1.14                0.25        0           F            
  Chinese            5,696              0.92 (0.82, 1.04)      1.34                0.18                0           F                        
  GT vs GG+TT        Overall            6,073                  0.96 (0.86, 1.08)   0.70                0.49        0           F            
  Chinese            5,696              0.97 (0.85, 1.10)      0.50                0.62                0           F                        
  TT vs GG           Overall            4,358                  0.81 (0.59, 1.12)   1.26                0.21        0           F            
  Chinese            4,184              0.71 (0.49, 1.04)      1.76                0.08                0           F                        
  T vs G             Overall            12,146                 0.93 (0.85, 1.03)   1.38                0.17        0           F            
  Chinese            11,392             0.92 (0.83, 1.02)      1.66                0.10                0           F                        
  rs920778 (C/T)     TT vs CC+CT        Overall                11,442              1.73 (1.30, 2.30)   3.79        0.01        77           R
  Chinese            10,508             2.21 (1.72, 2.85)      6.15                0.01                61          R                        
  TT+CT vs CC        Overall            11,442                 1.40 (1.16, 1.70)   3.45                0.01        72          R            
  Chinese            10,508             1.55 (1.43, 1.69)      10.22               0.01                43          F                        
  CT vs CC+TT        Overall            11,442                 1.10 (0.91, 1.32)   0.99                0.32        77          R            
  Chinese            10,508             1.20 (0.97, 1.48)      1.71                0.09                81          R                        
  TT vs CC           Overall            7,357                  1.83 (1.25, 2.68)   3.10                0.01        79          R            
  Chinese            6,853              2.76 (2.31, 3.29)      11.22               0.01                0           F                        
  T vs C             Overall            22,884                 1.37 (1.18, 1.59)   4.10                0.01        79          R            
  Chinese            21,016             1.56 (1.41, 1.74)      8.26                0.01                53          R                        

**Abbreviations:** F, fixed-effects model; OR, odds ratio; HOTAIR, HOX transcript antisense intergenic RNA; R, random-effects model; SNP, single-nucleotide polymorphism.
